Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms (Q83200641)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19151766%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

title

Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19151766%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19151766%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Jorma A Määttä

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19151766%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Klaus Elenius

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19151766%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

L Bald

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19151766%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

M X Sliwkowski

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19151766%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

19 January 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19151766%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19151766%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19151766%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19151766%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

1309-1319

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19151766%20AND%20SRC:MED&resulttype=core&format=json

describes a project that uses

20 January 2020

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2008.481

0 references

cites work

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

Back signaling by the Nrg-1 intracellular domain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

TACE is required for the activation of the EGFR by TGF-alpha in tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

Improving the efficacy of antibody-based cancer therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

Ectodomain cleavage of ErbB-4: characterization of the cleavage site and m80 fragment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

Somatic mutations affect key pathways in lung adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

Membrane targeting of Rab GTPases is influenced by the prenylation motif

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

ERBB receptors and cancer: the complexity of targeted inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

Intra- and extracellular signaling by endothelial neuregulin-1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

Erbb4 and its isoforms: selective regulation of growth factor responses by naturally occurring receptor variants.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

Ligand-independent degradation of epidermal growth factor receptor involves receptor ubiquitylation and Hgs, an adaptor whose ubiquitin-interacting motif targets ubiquitylation by Nedd4.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

Presenilin-dependent gamma-secretase-like intramembrane cleavage of ErbB4.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

The EGF receptor family as targets for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

The E3 ligase Aip4/Itch ubiquitinates and targets ErbB-4 for degradation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

ErbB4 and its isoforms: patentable drug targets?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

Mammalian cell transient expression of tissue factor for the production of antigen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

Nuclear signaling by receptor tyrosine kinases: the first robin of spring

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

Role of ErbB4 in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

Selective cleavage of the heregulin receptor ErbB-4 by protein kinase C activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481

secErbB4-26/549 antagonizes ligand-induced ErbB4 tyrosine phosphorylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.481